Eyenovia Closes $5.14 Million Public Offering
![Eyenovia Closes $5.14 Million Public Offering](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Eyenovia Announces Closure of Public Offering
Eyenovia, Inc. (NASDAQ: EYEN), a leading ophthalmic technology company, has announced the successful closing of its public offering, which involved the sale of 12,850,000 shares of common stock at a price of $0.40 per share. This offering has generated gross proceeds of approximately $5.14 million for the Company.
Utilization of Proceeds from the Offering
The funds raised from this public offering will be allocated towards several key initiatives. Primarily, Eyenovia intends to use the net proceeds to support commercialization activities for its innovative products, Mydcombi and Clobetasol Propionate. In addition, the capital will facilitate the completion of the CHAPERONE pediatric myopia clinical study. Furthermore, it will serve general corporate purposes, including the repayment of a portion of Eyenovia's existing debt.
Role of Placement Agent
Dawson James Securities, Inc. served as the placement agent for this offering, managing the sales and distribution process to help ensure its success.
Regulatory Compliance
The securities offered by Eyenovia were in accordance with its previously filed shelf registration statement on Form S-3, which received effective approval from the Securities and Exchange Commission. The offering details were made available through a prospectus supplement and an accompanying base prospectus.
Availability of Offering Documents
Interested parties could access the prospectus supplement and the base prospectus via the SEC's website or by contacting Dawson James Securities for additional copies.
About Eyenovia, Inc.
Eyenovia, Inc. is at the forefront of ophthalmic technology, focusing on the commercialization of Mydcombi™, an ophthalmic spray for mydriasis, and Clobetasol Propionate Ophthalmic Suspension for managing postsurgical inflammation and pain. The company is also advancing the development of the Optejet® device, which aims to enhance drug delivery for pediatric progressive myopia and may be licensed for other uses.
Expertise and Future Outlook
Looking ahead, Eyenovia is positioning itself to maximize shareholder value through its strategic initiatives and clinical advancements. The company is focused on progressing its product pipeline and exploring potential market opportunities.
Contact Information
For inquiries, Eyenovia can be reached through the following contacts:
Eyenovia Contact:
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
Frequently Asked Questions
What is Eyenovia's recent public offering about?
Eyenovia raised approximately $5.14 million through a public offering of 12,850,000 shares of common stock.
How will Eyenovia use the proceeds from the offering?
The funds will be used to support commercialization activities, clinical studies, and general corporate purposes.
Who acted as the placement agent for the offering?
Dawson James Securities, Inc. served as the placement agent for this public offering.
What products are associated with Eyenovia?
Eyenovia's key products include Mydcombi and Clobetasol Propionate Ophthalmic Suspension.
What is the future direction of Eyenovia?
Eyenovia is focused on advancing its product pipeline and maximizing shareholder value through strategic initiatives.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- IVF Service Market Expected to Reach USD 4838.7 Million
- Keywords Studios Plc: Public Opening Position Disclosure
- Nuwellis Announces $916,000 Registered Direct Offering
- Man Group PLC Discloses Stake in Keywords Studios plc
- Eckoh Plc Public Dealing Disclosure Overview
- Sodexo Completes €918 Million Sale of Sofinsod
- Gabelli Utility Trust Announces Rights Offering Details
- Ibotta Approves $100 Million Stock Buyback Program
- Soulbound Secures $4 Million to Revolutionize Web3 Gaming
- AvidXchange Board Approves $100 Million Share Repurchase Plan